81
edits
Changes
Jump to navigation
Jump to search
Created page with "The [https://serimmune.com/covid19study/ Serimmune COVID-19 Study] is a longitudinal research study conducted by the Serimmune company. The study uses the company's "Serum Epi..."
The [https://serimmune.com/covid19study/ Serimmune COVID-19 Study] is a longitudinal research study conducted by the Serimmune company. The study uses the company's "Serum Epitope Repertoire Analysis (SERA) technology" to study antibody responses, especially in the context of COVID-19 vaccination and exposure.
The study returns research-grade results (not intended for diagnostic clinical use) to participants. As described in the [https://serimmune.com/caspio-content/COVID-19-Study-Consent-Form-and-Bill-of-Rights-Preview.pdf study consent document], these results are not clinically validated and not meant to serve as a clinical assay. They are, nevertheless, interesting to look at!
The study is planned to last five years, with blood samples collected every six months. Samples are self-collected by participants using a home collection kit and sent by mail.
{{Project Infobox|Self researchers=User:Madprime |Related tools= |Related topics= }}
=SARS-CoV-2 Antibody Analyses=
==Vaccine-only responses==
{| class="wikitable"
|-
! Individual !! Date !! Report !! Notes
|-
| [[User:Madprime]] || 2022-02-03 || [[File:TOEAIX_20220203.pdf]] || Moderna vaccine (two shots, plus booster)
|}
==Post-exposure responses==
None yet; [[User:Madprime]] anticipates having one as they were infected with COVID-19 (positive home antigen test on 2022-05-01).
=Other results=
In addition to COVID-19 related antibody analyses, the study shares research analysis of antibodies related to infectious diseases (Lyme Disease, Ehrlichiosis, Anaplasmosis, Babesiosis, Chagas Disease) and autoimmune conditions (Celiac Disease).
{| class="wikitable"
|-
! Individual !! Date !! Report !! Notes
|-
| [[User:Madprime]] || 2022-02-03 || [[File:TOEAIX_Expanded_20220203.pdf]] || No medical history related to these analyses.
|}
{{Project Queries}}
[[Category:Projects]]
The study returns research-grade results (not intended for diagnostic clinical use) to participants. As described in the [https://serimmune.com/caspio-content/COVID-19-Study-Consent-Form-and-Bill-of-Rights-Preview.pdf study consent document], these results are not clinically validated and not meant to serve as a clinical assay. They are, nevertheless, interesting to look at!
The study is planned to last five years, with blood samples collected every six months. Samples are self-collected by participants using a home collection kit and sent by mail.
{{Project Infobox|Self researchers=User:Madprime |Related tools= |Related topics= }}
=SARS-CoV-2 Antibody Analyses=
==Vaccine-only responses==
{| class="wikitable"
|-
! Individual !! Date !! Report !! Notes
|-
| [[User:Madprime]] || 2022-02-03 || [[File:TOEAIX_20220203.pdf]] || Moderna vaccine (two shots, plus booster)
|}
==Post-exposure responses==
None yet; [[User:Madprime]] anticipates having one as they were infected with COVID-19 (positive home antigen test on 2022-05-01).
=Other results=
In addition to COVID-19 related antibody analyses, the study shares research analysis of antibodies related to infectious diseases (Lyme Disease, Ehrlichiosis, Anaplasmosis, Babesiosis, Chagas Disease) and autoimmune conditions (Celiac Disease).
{| class="wikitable"
|-
! Individual !! Date !! Report !! Notes
|-
| [[User:Madprime]] || 2022-02-03 || [[File:TOEAIX_Expanded_20220203.pdf]] || No medical history related to these analyses.
|}
{{Project Queries}}
[[Category:Projects]]